These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2766661)

  • 1. The antihypertensive and renal activities of potassium canrenoate are associated with increased renal prostaglandin excretion.
    Castellani S; Scarti L; Chen JL; Del Rosso A; Carnovali M; Masotti G
    Clin Sci (Lond); 1989 Aug; 77(2):217-22. PubMed ID: 2766661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective stimulation of renal PGE2 by potassium canrenoate in essential hypertension.
    Castellani S; Scarti L; Masotti G; Del Rosso A; Chen JI; Neri Serneri GG
    Prog Clin Biol Res; 1989; 301():297-301. PubMed ID: 2678128
    [No Abstract]   [Full Text] [Related]  

  • 3. Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin.
    Niutta E; Cusi D; Colombo R; Tripodi G; Pellizzoni M; Pati P; Cesana B; Alberghini E; Barlassina C; Bianchi G
    Am J Hypertens; 1988 Oct; 1(4 Pt 1):364-71. PubMed ID: 3063286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and renal properties of potassium-sparing diuretics of the spirolactone group--I: Effects of SC-14266/371 (potassium canrenoate) on renal transport Na+, K+-ATPase activity.
    Osore H; Harrow TA
    Biochem Pharmacol; 1982 Dec; 31(24):4068-71. PubMed ID: 6130770
    [No Abstract]   [Full Text] [Related]  

  • 5. [Urinary prostaglandin levels in patients with arterial hypertension with benign and malignant course].
    Runikhin AIu; Nekrasova AA; Levitskaia IuV; Arabidze GG
    Kardiologiia; 1990 Jan; 30(1):12-7. PubMed ID: 2335858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion.
    Finotti P; Antonello A
    Clin Pharmacol Ther; 1982 Jul; 32(1):1-6. PubMed ID: 6282524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effect of potassium canrenoate administration on renin-angiotensin, kallikrein-kinin and prostaglandin systems.
    Lahera V; Cachofeiro V; Duran F; Cañizo FJ; Rodriguez FJ; Tresguerres JA
    Gen Pharmacol; 1988; 19(6):835-9. PubMed ID: 3068096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of short-term administration of cromakalim on renal hemodynamics and eicosanoid excretion in essential hypertension.
    Lebel M; Grose JH; Lacourcière Y
    Am J Hypertens; 1991 Sep; 4(9):740-4. PubMed ID: 1834087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of K+-canrenoate on the development of DOCA-salt hypertension.
    Vargas F; Haro JM; Jodar E; Soler A; Garcia del Rio C
    J Pharm Pharmacol; 1989 May; 41(5):335-8. PubMed ID: 2569521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of potassium canrenoate on the raised intracranial pressure.
    Node Y; Yajima K; Nakazawa S
    Nihon Ika Daigaku Zasshi; 1984 Apr; 51(2):264-5. PubMed ID: 6736215
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.
    Gudmundsson FF; Viste A; Myking OL; Grong K; Svanes K
    Surg Endosc; 2004 Oct; 18(10):1528-34. PubMed ID: 15791383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sodium and renal prostaglandin E2 in the maintenance of hypertension in the chronic phase of two-kidney one-clip renovascular hypertension in rabbits.
    Machida J; Ueda S; Yoshida M; Soejima H; Ikegami K
    Nephron; 1988; 49(1):74-80. PubMed ID: 3164091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary prostaglandin and prostaglandin metabolite excretion in patients with essential hypertension or hypertension with renal artery stenosis.
    Postma CT; de Boo T; Thomas CM; Thien T
    Neth J Med; 1995 Sep; 47(3):99-105. PubMed ID: 7566295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of age on prostaglandin E2 excretion in normal and hypertensive men.
    Mackenzie T; Zawada ET; Johnson MD; Green S
    Nephron; 1984; 38(3):178-82. PubMed ID: 6593599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium chloride as regulator of renal prostaglandin E2 production in patients with essential hypertension.
    Stahl RA; Jonassen AJ; Paravicini M; Schollmeyer P
    Klin Wochenschr; 1982 Jun; 60(11):579-81. PubMed ID: 7050523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal prostaglandin E2 and F2 alpha synthesis during exercise: effects of indomethacin and sulindac.
    Zambraski EJ; Dodelson R; Guidotti SM; Harnett CA
    Med Sci Sports Exerc; 1986 Dec; 18(6):678-84. PubMed ID: 3537627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary prostaglandin F2 alpha excretion is not pH-dependent in the conscious rat: implications for the urinary prostaglandin E2/prostaglandin F2 alpha ratio.
    Haylor J; Lote CJ
    Clin Sci (Lond); 1990 Feb; 78(2):181-4. PubMed ID: 2155746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.